ABOUT BIOSIMILAR DEVELOPMENT

The landscape of the life sciences industry is as vast and varied as the professionals who work in it. Some online resources aim to serve the entire space. We wish them luck. Instead, our goal is to be the most valuable resource for a specific segment of the industry – biosimilars – and the professionals who make their living there. The Biosimilar Development community is not made up of generalists. They’re specialists, like us. We deliver in-depth content from authoritative authors and sources because that’s what our community demands.

AUTHORITY

Chief Editor Anna Rose Welch

Since the launch of Biosimilar Development in 2015, Chief Editor Anna Rose Welch has conducted interviews and written thought-leadership columns on the biosimilar development, regulatory, policy, and commercialization advances in the global biosimilar industry. She has built an editorial board and interviewed experts from a wide variety of biosimilar stakeholder organizations. Here’s a sample of her latest articles for Biosimilar Development.

Anna Rose has also been an active participant in the biosimilar conferences circuit. She has been appointed chair or served as a speaker and panel moderator at conferences based in the U.S. and Europe, including the World Biosimilar Congress USA, The Biotech Pharma Summit, the CBI Biosimilars Summit, DIA Biosimilars Conference, and the Biosimilar Medicines Group Conference. In 2018, she was invited to Brazil to address members of the Brazilian Ministry of Health, ANVISA, and local biologics and biosimilars manufacturers about how to establish a national biologics and biosimilars policy. She has also represented the publication on a media tour of Bangkok, Thailand in 2017, during which she reported on the country’s efforts to bolster its life sciences industry.  In addition to writing for Biosimilar Development, she penned the introductory chapter to the book, Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (Springer, 2018).

In 2018, her first book of poetry was published by Alice James Books.

The Biosimilar Development Editorial Advisory Board is also pretty impressive.

CONTACT BIOSIMILAR DEVELOPMENT

Biosimilar Development is a product of Life Science Connect, a division of VertMarkets.

• Join the Biosimilar Development community
• Email general questions
• Submit/propose an article
• Request a media kit
• Join our team

Office Locations